The research progress in randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for advanced gastric cancer patients

Abstract

Background: There is differrence beteween the perioperative and adjuvant chemotherapy in east and west country, but there is no study to compare the effect between the perioperative and adjuvant chemotherapy based on the D2 gastrectomy in advanced gastric cancer till now. Our study wants to evaluate the efficacy and safety of S-1 and oxaliplatin as neoadjuvant chemotherapy for advanced gastric cancer. Method(s): Between September 2012 and December 2016, 420 patients with clinical stage IIA-IIIC gastric cancer were eligible for inclusion. They were randomly assigned to either the neoadjuvant chemotherapy group (n=210) or the adjuvant chemotherapy group (n=210). The reaction rate, effective rate, T-stage, incidences of adverse reaction, surgical R0 resection rate, CY1 rate and pCR rate in the two groups were compared. Result(s): In neoadjuvant chemotherapy group, the reaction rate, effective rate, and pCR rate were 80%, 40% and 20% respectively. The surgical R0 resection rate (80% vs 70%) were much higher in neoadjuvant chemotherapy group. There was no significant difference in incidences of adverse reaction between the two groups. However, the CY1 rate (5% vs 8%) was lower and T-stage was earlier in neoadjuvant chemotherapy group. Conclusion(s): S-1 and oxaliplatin as neoadjuvant chemotherapy is effective for advanced gastric cancer, and there was no increase of adverse reaction.